15.8% rise in short interest, 132,700 Altamira Therapeutics shares shorted by July end.
In July, Altamira Therapeutics Ltd., a Swiss-Australian preclinical biopharmaceutical firm, experienced a 15.8% rise in short interest, with 132,700 shares shorted by the month's end. This represents 6% of shares being sold short. The company develops OligoPhore/SemaPhore platforms, including the drug-free nasal spray Bentrio, and its shares traded at $0.96 on July 31st.
August 19, 2024
3 Articles